EGFR and non-small cell lung carcinoma: The multicenter phase II NEJ 001 study was undertaken to investigate the efficacy and feasibility of gefitinib treatment for advanced NSCLC patients harboring EGFR mutations but who were ineligible for chemotherapy due to poor performance status (PS) [39].